Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation

Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Richard Maziarz, Michael A. Pulsipher, Michael B. Maris, Smita Bhatia, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, Barry E. Storer

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

Patients and Methods: Data from 3,033 consecutive recipients of HLA-matched grafts from five institutions contributed to this analysis. Patients were randomly divided into a training set to develop weights for age ntervals and a validation set to assess the performance of prognostic models.

Purpose: Age has long been used as a major factor for assessing suitability for allogeneic hematopoietic cel transplantation (HCT). The HCT-comorbidity index (HCT-CI) was developed as a measure of health status to predict mortality risk after HCT. Whether age, comorbidities, or both should guide decision making for HCT is unknown.

Results: In the training set, patients age 20 to 39 years, 40 to 49 years, 50 to 59 years, and ≥ 60 years had hazard ratios for nonrelapse mortality (NRM) of 1.21 (P =.29), 1.48 (P =.04), 1.75 (P =.004), and 1.84 (P =.005), respectively, compared with those age younger than 20 years. Consequently, age ≥ 40 years was assigned a weight of 1 to be added to the HCT-CI to constitute a composite comorbidity/age index. In the validation set, the composite comorbidity/age score had statistically significantly higher c-statistic estimates for prediction of NRM (0.664 v 0.556; P

Conclusion: Age is a poor prognostic factor. The proposed composite measure allows integration of both comorbidities and age into clinical decision making and comparative-effectiveness research of HCT.

Original languageEnglish (US)
Pages (from-to)3249-3256
Number of pages8
JournalJournal of Clinical Oncology
Volume32
Issue number29
DOIs
StatePublished - Oct 10 2014

Fingerprint

Cell Transplantation
Comorbidity
Transplantation
Mortality
Comparative Effectiveness Research
Weights and Measures
Health Status
Decision Making
Transplants

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Sorror, M. L., Storb, R. F., Sandmaier, B. M., Maziarz, R., Pulsipher, M. A., Maris, M. B., ... Storer, B. E. (2014). Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation. Journal of Clinical Oncology, 32(29), 3249-3256. https://doi.org/10.1200/JCO.2013.53.8157

Comorbidity-age index : A clinical measure of biologic age before allogeneic hematopoietic cell transplantation. / Sorror, Mohamed L.; Storb, Rainer F.; Sandmaier, Brenda M.; Maziarz, Richard; Pulsipher, Michael A.; Maris, Michael B.; Bhatia, Smita; Ostronoff, Fabiana; Deeg, H. Joachim; Syrjala, Karen L.; Estey, Elihu; Maloney, David G.; Appelbaum, Frederick R.; Martin, Paul J.; Storer, Barry E.

In: Journal of Clinical Oncology, Vol. 32, No. 29, 10.10.2014, p. 3249-3256.

Research output: Contribution to journalArticle

Sorror, ML, Storb, RF, Sandmaier, BM, Maziarz, R, Pulsipher, MA, Maris, MB, Bhatia, S, Ostronoff, F, Deeg, HJ, Syrjala, KL, Estey, E, Maloney, DG, Appelbaum, FR, Martin, PJ & Storer, BE 2014, 'Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation', Journal of Clinical Oncology, vol. 32, no. 29, pp. 3249-3256. https://doi.org/10.1200/JCO.2013.53.8157
Sorror, Mohamed L. ; Storb, Rainer F. ; Sandmaier, Brenda M. ; Maziarz, Richard ; Pulsipher, Michael A. ; Maris, Michael B. ; Bhatia, Smita ; Ostronoff, Fabiana ; Deeg, H. Joachim ; Syrjala, Karen L. ; Estey, Elihu ; Maloney, David G. ; Appelbaum, Frederick R. ; Martin, Paul J. ; Storer, Barry E. / Comorbidity-age index : A clinical measure of biologic age before allogeneic hematopoietic cell transplantation. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 29. pp. 3249-3256.
@article{34a7f7b553434a97814ba6585b12b56c,
title = "Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation",
abstract = "Patients and Methods: Data from 3,033 consecutive recipients of HLA-matched grafts from five institutions contributed to this analysis. Patients were randomly divided into a training set to develop weights for age ntervals and a validation set to assess the performance of prognostic models.Purpose: Age has long been used as a major factor for assessing suitability for allogeneic hematopoietic cel transplantation (HCT). The HCT-comorbidity index (HCT-CI) was developed as a measure of health status to predict mortality risk after HCT. Whether age, comorbidities, or both should guide decision making for HCT is unknown.Results: In the training set, patients age 20 to 39 years, 40 to 49 years, 50 to 59 years, and ≥ 60 years had hazard ratios for nonrelapse mortality (NRM) of 1.21 (P =.29), 1.48 (P =.04), 1.75 (P =.004), and 1.84 (P =.005), respectively, compared with those age younger than 20 years. Consequently, age ≥ 40 years was assigned a weight of 1 to be added to the HCT-CI to constitute a composite comorbidity/age index. In the validation set, the composite comorbidity/age score had statistically significantly higher c-statistic estimates for prediction of NRM (0.664 v 0.556; P Conclusion: Age is a poor prognostic factor. The proposed composite measure allows integration of both comorbidities and age into clinical decision making and comparative-effectiveness research of HCT.",
author = "Sorror, {Mohamed L.} and Storb, {Rainer F.} and Sandmaier, {Brenda M.} and Richard Maziarz and Pulsipher, {Michael A.} and Maris, {Michael B.} and Smita Bhatia and Fabiana Ostronoff and Deeg, {H. Joachim} and Syrjala, {Karen L.} and Elihu Estey and Maloney, {David G.} and Appelbaum, {Frederick R.} and Martin, {Paul J.} and Storer, {Barry E.}",
year = "2014",
month = "10",
day = "10",
doi = "10.1200/JCO.2013.53.8157",
language = "English (US)",
volume = "32",
pages = "3249--3256",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "29",

}

TY - JOUR

T1 - Comorbidity-age index

T2 - A clinical measure of biologic age before allogeneic hematopoietic cell transplantation

AU - Sorror, Mohamed L.

AU - Storb, Rainer F.

AU - Sandmaier, Brenda M.

AU - Maziarz, Richard

AU - Pulsipher, Michael A.

AU - Maris, Michael B.

AU - Bhatia, Smita

AU - Ostronoff, Fabiana

AU - Deeg, H. Joachim

AU - Syrjala, Karen L.

AU - Estey, Elihu

AU - Maloney, David G.

AU - Appelbaum, Frederick R.

AU - Martin, Paul J.

AU - Storer, Barry E.

PY - 2014/10/10

Y1 - 2014/10/10

N2 - Patients and Methods: Data from 3,033 consecutive recipients of HLA-matched grafts from five institutions contributed to this analysis. Patients were randomly divided into a training set to develop weights for age ntervals and a validation set to assess the performance of prognostic models.Purpose: Age has long been used as a major factor for assessing suitability for allogeneic hematopoietic cel transplantation (HCT). The HCT-comorbidity index (HCT-CI) was developed as a measure of health status to predict mortality risk after HCT. Whether age, comorbidities, or both should guide decision making for HCT is unknown.Results: In the training set, patients age 20 to 39 years, 40 to 49 years, 50 to 59 years, and ≥ 60 years had hazard ratios for nonrelapse mortality (NRM) of 1.21 (P =.29), 1.48 (P =.04), 1.75 (P =.004), and 1.84 (P =.005), respectively, compared with those age younger than 20 years. Consequently, age ≥ 40 years was assigned a weight of 1 to be added to the HCT-CI to constitute a composite comorbidity/age index. In the validation set, the composite comorbidity/age score had statistically significantly higher c-statistic estimates for prediction of NRM (0.664 v 0.556; P Conclusion: Age is a poor prognostic factor. The proposed composite measure allows integration of both comorbidities and age into clinical decision making and comparative-effectiveness research of HCT.

AB - Patients and Methods: Data from 3,033 consecutive recipients of HLA-matched grafts from five institutions contributed to this analysis. Patients were randomly divided into a training set to develop weights for age ntervals and a validation set to assess the performance of prognostic models.Purpose: Age has long been used as a major factor for assessing suitability for allogeneic hematopoietic cel transplantation (HCT). The HCT-comorbidity index (HCT-CI) was developed as a measure of health status to predict mortality risk after HCT. Whether age, comorbidities, or both should guide decision making for HCT is unknown.Results: In the training set, patients age 20 to 39 years, 40 to 49 years, 50 to 59 years, and ≥ 60 years had hazard ratios for nonrelapse mortality (NRM) of 1.21 (P =.29), 1.48 (P =.04), 1.75 (P =.004), and 1.84 (P =.005), respectively, compared with those age younger than 20 years. Consequently, age ≥ 40 years was assigned a weight of 1 to be added to the HCT-CI to constitute a composite comorbidity/age index. In the validation set, the composite comorbidity/age score had statistically significantly higher c-statistic estimates for prediction of NRM (0.664 v 0.556; P Conclusion: Age is a poor prognostic factor. The proposed composite measure allows integration of both comorbidities and age into clinical decision making and comparative-effectiveness research of HCT.

UR - http://www.scopus.com/inward/record.url?scp=84907533471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907533471&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.53.8157

DO - 10.1200/JCO.2013.53.8157

M3 - Article

C2 - 25154831

AN - SCOPUS:84907533471

VL - 32

SP - 3249

EP - 3256

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 29

ER -